Reason: Filed for Bankruptcy
Last recorded trade on: September 27, 2023
Source: https://www.fiercebiotech.com/medtech/viewray-eyes-sale-mri-guided-radiotherapy-tech-wake-bankruptcy-filing
P/E ratio for ViewRay (VRAY)
P/E ratio on September 27, 2023 (TTM): -0.0431
According to ViewRay's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.0431034. At the end of 2022 the company had a P/E ratio of -7.72.
P/E ratio history for ViewRay from 2015 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -7.72 | -6.08% |
| 2021 | -8.22 | 59.31% |
| 2020 | -5.16 | 44.34% |
| 2019 | -3.58 | -42.85% |
| 2018 | -6.26 | -14.85% |
| 2017 | -7.35 | 198.19% |
| 2016 | -2.46 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 | -0.0431 | 0.00% | 🇺🇸 USA |
 | 17.3 | -40,261.10% | 🇺🇸 USA |
 | -3.45 | 7,907.33% | 🇮🇱 Israel |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.